Qtron Investments LLC Has $466,000 Position in GSK PLC Sponsored ADR $GSK

Key Points

• Qtron Investments LLC reduced its holdings in GSK PLC by 48.1% during the first quarter, selling 11,154 shares and leaving them with 12,021 shares valued at $466,000.
• GSK reported earnings of $1.23 per share, surpassing analysts' expectations of $1.12, with quarterly revenue of $10.64 billion that also exceeded predictions.
• The company has declared a quarterly dividend of $0.4206, resulting in a 4.3% dividend yield and a payout ratio of 77.78%.

Qtron Investments LLC decreased its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 48.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,021 shares of the pharmaceutical company's stock after selling 11,154 shares during the quarter. Qtron Investments LLC's holdings in GSK were worth $466,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GSK. Voloridge Investment Management LLC lifted its position in GSK by 1,360.4% in the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after buying an additional 2,016,795 shares in the last quarter. Woodline Partners LP bought a new position in shares of GSK during the 4th quarter valued at $36,665,000. Miller Howard Investments Inc. NY raised its holdings in shares of GSK by 138.4% during the 1st quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock valued at $63,797,000 after purchasing an additional 955,891 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of GSK by 68.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,237,034 shares of the pharmaceutical company's stock valued at $75,656,000 after purchasing an additional 907,068 shares in the last quarter. Finally, Kahn Brothers Group Inc. bought a new position in shares of GSK during the 4th quarter valued at $29,921,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Performance

GSK traded up $0.0650 during trading on Friday, hitting $40.1450. The stock had a trading volume of 3,403,643 shares, compared to its average volume of 3,878,580. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The firm has a market cap of $81.80 billion, a PE ratio of 18.59, a P/E/G ratio of 1.74 and a beta of 0.51. The company has a 50 day simple moving average of $38.34 and a 200-day simple moving average of $38.11. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.67.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The business's quarterly revenue was up 1.3% on a year-over-year basis. During the same period last year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 4.2%. The ex-dividend date is Friday, August 15th. GSK's dividend payout ratio (DPR) is currently 77.78%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on GSK shares. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, Wall Street Zen upgraded shares of GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Seven research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.